AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender

Contract notice: conclusion of non-exclusive discount agreements according to § 130a para. 8 sgb v on drugs with the active ingredient lamivudine, tenofovir disoproxil and doravirine (j05ar24) as part of an open-house model. Conclusion of non-exclusive discount agreements according to § 130a para. 8 sgb v for medicinal products with the active ingredients lamivudine, tenofovir disoproxil and doravirine (j05ar24) within the period from 06/01/2022 to 05/31/2024 with the possibility of concluding a contract at any time (open-house model).The aok rhineland-palatinate/saarland - the health insurance fund offers all interested pharmaceutical companies discount contracts with the active ingredients lamivudine, tenofovir disoproxil and doravirine (j05ar24) without a selection decision. the contracts are concluded within the framework of an open house model . the contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by the aok rheinland-pfalz/saarland - the health insurance company. in the open house model, the same conditions apply to all participants. contract content, conditions and access procedures are uniform - individual negotiations are not conducted. the contract terms are a maximum of 24 months, the earliest start of the contract is 06/01/2022. all contracts end no later than 24 months after the date of the earliest start of the contract, regardless of the date of the respective conclusion of the contract. a membership or a contract can be concluded within the 24-month period on the first of each month. there is a right of termination six weeks to the end of the month in accordance with the provisions of the contract. further information on the termination options is contained in the contract documents. the aok rheinland-pfalz/saarland - the health insurance company reserves the right to replace the non-exclusive open house discount contracts with exclusive discount contracts during the contract period as part of the europe-wide tendering process. with the entry into force of advertised, exclusive discount contracts, the open house contracts are terminated in accordance with the contractual provisions, i.E. the open house contracts end automatically. interested pharmaceutical companies can request the participation documents and contract documents from the contact address given under i.1). contracts for the active ingredients lamivudine, tenofovir disoproxil and doravirine (j05ar24) will be concluded for the first time with effect from june 1st, 2022. interested parties who would like to become a contractual partner on this date must submit the contract documents to the aok rheinland-pfalz/saarland - the health insurance company by 04/30/2022. it depends on the access to the aok rheinland-pfalz/saarland - the health fund. note: the first contract in this procedure will be awarded no earlier than 10 calendar days after publication of this eu announcement in the official gazette. later